AI Article Synopsis
- Interest in tricuspid regurgitation (TR) has increased due to studies linking higher TR severity to worse patient outcomes, even considering other health conditions.
- Due to high in-hospital mortality with traditional surgery for TR, new less invasive transcatheter treatment options have been developed.
- The first document from the Tricuspid Valve Academic Research Consortium aims to standardize definitions and endpoints for research trials to improve understanding and management of TR, with a follow-up document planned to focus on trial design and further endpoint definitions.
Article Abstract
Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2023.09.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!